BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2023

Mar 2, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2023-02-28

Reporting Person: FUCHS HENRY J (President, Worldwide R&D)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-02-28	Common Stock	A	36440	$0.00	Acquired	180534	Direct
2023-02-28	Common Stock	A	18220	$0.00	Acquired	198754	Direct
2023-02-28	Common Stock	A	13392	$0.00	Acquired	212146	Direct

Footnotes

F1: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.

F2: Represents the total number of RSUs earned pursuant to a formula based on relative total shareholder return during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

F3: Although earned, the RSUs only vest according to the following schedule: vests on March 16, 2023, subject to the reporting person's continued service through that date, subject to earlier vesting upon certain events.

F4: Represents the total number of RSUs earned pursuant to a formula based on the number and nature of strategic goals achieved during 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.

F5: Represents the total number of RSUs earned pursuant to a formula based on non-GAAP income over three, one-year periods spanning 2020 through 2022 set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan.